NCT03373188 - VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

October 28, 2021

Study Completion Date

October 28, 2021

Conditions

Colon Carcinoma Metastatic in the LiverColorectal AdenocarcinomaPancreatic AdenocarcinomaResectable Pancreatic CarcinomaStage I Pancreatic CancerStage IA Pancreatic CancerStage IB Pancreatic CancerStage II Pancreatic CancerStage IIA Pancreatic CancerStage IIB Pancreatic CancerStage III Pancreatic CancerStage IV Colorectal CancerStage IVA Colorectal CancerStage IVB Colorectal Cancer

Interventions

BIOLOGICAL

Anti-SEMA4D Monoclonal Antibody VX15/2503

Given IV

BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

PROCEDURE

Surgery

Undergo therapeutic conventional surgery

Trial Locations (4)

14642

University of Rochester Medical Center, Rochester

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

All Listed Sponsors

collaborator

Vaccinex Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Emory University

OTHER